feed,title,long_url,short_url
Benzinga,FDA Clears Turning Point's IND For Elzovantinib + Aumolertinib Combo Regime In Lung Cancer Setting,https://benzinga.com/general/biotech/22/01/25136756/fda-clears-turning-points-ind-for-elzovantinib-aumolertinib-combo-regime-in-lung-cancer-setting,https://bit.ly/3nInhZc
Benzinga,FDA Gives Green Signal To Compass Therapeutics' Mid-Stage Biliary Tract Cancer Trial In US,https://benzinga.com/general/biotech/22/01/25134417/fda-gives-green-signal-to-compass-therapeutics-mid-stage-biliary-tract-cancer-trial-in-us,https://bit.ly/3qHfcFU
Benzinga,Citi Cuts Microsoft Price Target By 8%,https://benzinga.com/analyst-ratings/analyst-color/22/01/25135342/citi-cuts-microsoft-price-target-by-8,https://bit.ly/3qLwi5s
